This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Incyte's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Incyte Corporation (INCY)

Q2 2012 Earnings Call

August 2, 2012 08:30 am ET


Paul Friedman – President & Chief Executive Officer

Patricia Andrews – Executive Vice President & Chief Commercial Officer

Dave Hastings – Executive Vice President & Chief Financial Officer

Rich Levy – Executive Vice President & Chief Drug Development and Medical Officer

Pamela Murphy – Vice President, Investor Relations and Corporate Communications


Matt Roden – UBS

Brian Abrahams – Wells Fargo

Salveen Richter – Canaccord Genuity

Ian Somaiya – Piper Jaffray

Cory Kasimov – JP Morgan

Thomas Wei – Jefferies & Co.

Rachel McMinn – Bank of America

Tom Russo – Robert W. Baird

Lisa Bayko – JMP Securities

Eric Schmidt – Cowen & Company

Christina – Barclays Capital

David Friedman – Morgan Stanley

Boris Peaker – Oppenheimer

David Crump – Morningstar

Mani Mohindru – ThinkEquity



Greetings, ladies and gentlemen, and welcome to the Incyte Corporation’s Q2 2012 Earnings Call. A brief question-and-answer session will follow the formal presentation. (Operator instructions.) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ms. Pamela Murphy, Vice President Investor Relations and Communications. Thank you Ms. Murphy, you may now begin.

Pamela Murphy

Good morning and welcome to Incyte’s Q2 2012 conference call. On the call today are Paul Friedman, Incyte’s President and Chief Executive Officer; Pat Andrews, Executive Vice President and Chief Commercial Officer; Dave Hastings, Executive Vice President and Chief Financial Officer; and Rich Levy, Executive Vice President and Chief Drug Development and Medical Officer. Pat is traveling outside of the country right now and is therefore not in the room with us. Paul will begin with a brief overview of the quarter, Pat will update you on the product launch of Jakafi, and Dave will describe the Q2 2012 financial results.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,155.41 +58.51 0.32%
S&P 500 2,102.34 +3.81 0.18%
NASDAQ 4,987.6840 +20.5430 0.41%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs